Fixed dose combination formulations of rifaximin and lactulose
AssigneeOakdene Holdings LLC
InventorsJames Garegnani, Aman Trehan
Life of this patent
Estimating the term…
Abstract
A fixed dose combination formulation of rifaximin or a pharmaceutically acceptable salt thereof and lactulose is provided. The formulation is used for the prevention, treatment, or maintaining remission of HE; reducing the recurrence of HE episodes; reducing the recurrence of HE episodes in a patient refractory or non-responsive to rifaximin or lactulose monotherapy; or reducing the frequency of hospital visit.
Claims20
An oral formulation comprising fixed dose combination of rifaximin or a pharmaceutically acceptable salt thereof and lactulose for preventing, treating, or maintaining remission of hepatic encephalopathy.
An oral formulation comprising fixed dose combination of rifaximin or a pharmaceutically acceptable salt thereof and lactulose for treating, preventing or maintaining remission of hepatic encephalopathy, wherein once-a-day administration of said suspension provides steady state blood levels of rifaximin or lactulose that are comparable to steady state blood levels of rifaximin or lactulose achieved with simultaneous administration of separate dosage forms containing the same amount of rifaximin and lactulose.
Dependencies are inferred from the claim text.